Evidence-based safety information about medication, vaccine, chemical and radiological exposures in pregnancy
Clopidogrel in pregnancy
Clopidogrel may be required during pregnancy for some women with cardiovascular conditions, yet evidence regarding its safety remains limited. Our latest systematic review critically evaluates the available data on pregnancy outcomes following clopidogrel exposure and summarises current clinical guidance and key knowledge gaps.
Asthma monoclonal antibody therapies
We have published new systematic evidence reviews on the use of monoclonal antibody (mAb) therapies licensed for the management of asthma in the UK. We now have information available on the use of mepolizumab, reslizumab, benralizumab, omalizumab, dupilumab, and tezepelumab in pregnancy.
CFTR modulators in pregnancy
We have published a new systematic evidence review on the safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators (CFTRm) in pregnancy. Their use has been associated with a marked increase in pregnancies among women with cystic fibrosis, but data on maternal and fetal safety is limited. This review aims to support decision-making around continuing treatment in pregnancy.
Nausea and vomiting in pregnancy
We are excited to share our animation on treatment of nausea and vomiting during pregnancy. The animation has been designed with women who do not speak English as their first language so that more pregnant women can make informed choices about healthcare. The animations can be found on our medicinesinpregnancy.org website here.
Janus kinase inhibitors (JAK-Is) in pregnancy
We have published a new systematic evidence review on the safety of janus kinase inhibitors (JAK-Is) in pregnancy. Given the data limitations, the use of JAK-Is in pregnancy should be reserved for situations where alternative treatments, with better quality pregnancy safety data, are either not appropriate or do not provide adequate control of the maternal condition.
GLP1 receptor agonists in pregnancy
For up to date information on the use of GLP1 receptor agonists in pregnancy please see our systematic evidence review here. Data are currently limited and more information is required about their safety in pregnancy. Please encourage women who have conceived on a GLP1 receptor agonist to record their pregnancy on the MyBUMP portal.
Latest papers from the field of teratology
Safety signals from the EUROmediCAT network
Sibling-controlled cohort study of paracetamol use in pregnancy and the risk of ASD or ADHD
Who are UKTIS?
UKTIS is commissioned by the UK Health Security Agency (UKHSA) and hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust to perform national surveillance of known and emerging human teratogens.
Information collected by UKTIS is recognised by the Caldicott Advisory Panel of UKHSA.